1.Reverse Takotsubo pattern stress cardiomyopathy in a male patient induced during dobutamine stress echocardiography.
Annals of the Academy of Medicine, Singapore 2012;41(6):264-264
Aspirin
;
therapeutic use
;
Bisoprolol
;
therapeutic use
;
Cardiomyopathies
;
chemically induced
;
etiology
;
Cardiotonic Agents
;
adverse effects
;
Chest Pain
;
diagnostic imaging
;
Dobutamine
;
adverse effects
;
Echocardiography, Stress
;
adverse effects
;
Enalapril
;
therapeutic use
;
Humans
;
Male
;
Middle Aged
;
Simvastatin
;
therapeutic use
2.Impact of the beta-1 adrenergic receptor polymorphism on tolerability and efficacy of bisoprolol therapy in Korean heart failure patients: association between beta adrenergic receptor polymorphism and bisoprolol therapy in heart failure (ABBA) study.
Hae Young LEE ; Wook Jin CHUNG ; Hui Kyung JEON ; Hong Seog SEO ; Dong Ju CHOI ; Eun Seok JEON ; Jae Joong KIM ; Joon Han SHIN ; Seok Min KANG ; Sung Cil LIM ; Sang Hong BAEK
The Korean Journal of Internal Medicine 2016;31(2):277-287
BACKGROUND/AIMS: We evaluated the association between coding region variants of adrenergic receptor genes and therapeutic effect in patients with congestive heart failure (CHF). METHODS: One hundred patients with stable CHF (left ventricular ejection fraction [LVEF] < 45%) were enrolled. Enrolled patients started 1.25 mg bisoprolol treatment once daily, then up-titrated to the maximally tolerable dose, at which they were treated for 1 year. RESULTS: Genotypic analysis was carried out, but the results were blinded to the investigators throughout the study period. At position 389 of the beta-1 adrenergic receptor gene (ADRB1), the observed minor Gly allele frequency (Gly389Arg + Gly389Gly) was 0.21, and no deviation from Hardy-Weinberg equilibrium was observed in the genotypic distribution of Arg389Gly (p = 0.75). Heart rate was reduced from 80.8 +/- 14.3 to 70.0 +/- 15.0 beats per minute (p < 0.0001). There was no significant difference in final heart rate across genotypes. However, the Arg389Arg genotype group required significantly more bisoprolol compared to the Gly389X (Gly389Arg + Gly389Gly) group (5.26 +/- 2.62 mg vs. 3.96 +/- 2.05 mg, p = 0.022). There were no significant differences in LVEF changes or remodeling between two groups. Also, changes in exercise capacity and brain natriuretic peptide level were not significant. However, interestingly, there was a two-fold higher rate of readmission (21.2% vs. 10.0%, p = 0.162) and one CHF-related death in the Arg389Arg group. CONCLUSIONS: The ADRB1 Gly389X genotype showed greater response to bisoprolol than the Arg389Arg genotype, suggesting the potential of individually tailoring beta-blocker therapy according to genotype.
Adrenergic beta-1 Receptor Antagonists/adverse effects/*therapeutic use
;
Adult
;
Aged
;
Bisoprolol/adverse effects/*therapeutic use
;
Female
;
Gene Frequency
;
Genotype
;
Heart Failure/diagnosis/*drug therapy/*genetics/physiopathology
;
Heart Rate/drug effects
;
Humans
;
Male
;
Maximum Tolerated Dose
;
Middle Aged
;
Pharmacogenomic Testing
;
Phenotype
;
*Polymorphism, Genetic
;
Precision Medicine
;
Receptors, Adrenergic, beta-1/*drug effects/*genetics
;
Republic of Korea
;
Stroke Volume/drug effects
;
Time Factors
;
Treatment Outcome
;
Ventricular Function, Left/drug effects
;
Ventricular Remodeling/drug effects